License Agreements - Innovent (Details) - Innovent - USD ($) $ in Millions |
1 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Jan. 31, 2019 |
Dec. 31, 2018 |
Dec. 31, 2020 |
Dec. 31, 2019 |
Dec. 31, 2018 |
|
License agreements | |||||
Upfront and immediate milestone payment to be received under license agreement | $ 40.0 | ||||
Research and development expenses reimbursed | $ 5.4 | $ 6.2 | |||
Reimbursable costs included in accounts receivable | 1.2 | 3.0 | |||
Development and Regulatory Milestones | |||||
License agreements | |||||
Amount recognized and received for the achievement of a predefined milestone | $ 20.0 | ||||
Development and Regulatory Milestones | Maximum | |||||
License agreements | |||||
Upfront and immediate milestone payment to be received under license agreement | $ 129.0 | ||||
Development and Regulatory Milestones | PEMAZYRE | |||||
License agreements | |||||
Amount recognized and received for the achievement of a predefined milestone | $ 5.0 | ||||
Sales and Commercial Milestones | Maximum | |||||
License agreements | |||||
Upfront and immediate milestone payment to be received under license agreement | $ 202.5 |